Nanoscope Therapeutics said that results from its long-term extension study, named REMAIN, demonstrate durable vision improvement following treatment with its optogenetic therapy MCO-010 in patients with advanced retinitis pigmentosa (RP).
The company said that through 152 weeks of follow-up, patients treated with a single intravitreal injection of MCO-010 maintained an average best corrected visual acuity (BCVA) gain of approximately 0.3 LogMAR, equivalent to three lines or fifteen letters on a standard ETDRS chart.
Nanoscope claims that the BCVA area-under-the-curve profiles from the combined RESTORE and REMAIN trials show five-fold greater vision gains than sham-treated controls.
In terms of safety, the company said that no serious ocular adverse events were reported among treated patients and that the therapy was generally well tolerated; only one mild case of inflammation required topical steroids and most patients required no ongoing management at Week 152.
Nanoscope said that the data form the basis of a rolling Biologics License Application with the U.S. Food and Drug Administration (FDA) for RP and highlight the potential of its broader MCO platform as a one-time, disease-agnostic therapy for retinal degenerative conditions.
